Jin-Shing Chen

Prof. Jin-Shing Chen

Department of Surgery, National Taiwan University Cancer Center, National Taiwan University College of Medicine, Taipei 106037, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Cell
Verified
Journal Article
Open access
Yi-Ju ChenYi-Ju Chen
Yi-Ju Chen
TRTheodoros I. Roumeliotis
Theodoros I. Roumeliotis
YCYa-Hsuan Chang
Ya-Hsuan Chang
CCChing-Tai Chen
Ching-Tai Chen
CHChia-Li Han
Chia-Li Han
Yu-Ju ChenYu-Ju Chen
Yu-Ju Chen
Lung cancer in East Asia is characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations. To illuminate the molecular phenotype of this demographically distinct disease, we performed a deep comprehensive proteogenomic study on a prospectively collected cohort in Taiwan, representing early stage, predominantly female, non-smoking lung adenocarcinoma. Integrated genomic, proteomic, and phosphoproteomic analysis delineated the demographically distinct molecular attributes and hallmarks of tumor progression. Mutational signature analysis revealed age- and gender-related mutagenesis mechanisms, characterized by high prevalence of APOBEC mutational signature in younger females and over-representation of environmental carcinogen-like mutational signatures in older females. A proteomics-informed classification distinguished the clinical characteristics of early stage patients with EGFR mutations. Furthermore, integrated protein network analysis revealed the cellular remodeling underpinning clinical trajectories and nominated candidate biomarkers for patient stratification and therapeutic intervention. This multi-omic molecular architecture may help develop strategies for management of early stage never-smoker lung adenocarcinoma.

1 December 2011 in Annals of Surgery
Verified
Journal Article
Closed access
JCJin-Shing Chen
Jin-Shing Chen
YCYa-Jung Cheng
Ya-Jung Cheng
MHMing-Hui Hung
Ming-Hui Hung
YTYu-Ding Tseng
Yu-Ding Tseng
KCKe-Cheng Chen
Ke-Cheng Chen
YLYung-Chie Lee
Yung-Chie Lee
To evaluate the feasibility and safety of thoracoscopic lobectomy without endotracheal intubation. General anesthesia with single-lung ventilation is considered mandatory for thoracoscopic lobectomy for non-small cell lung cancer (NSCLC). Nonintubated thoracoscopic lobectomy has not been reported previously. From August 2009 through June 2010, some 30 consecutive patients with clinical stage I or II NSCLC were treated by nonintubated thoracoscopic lobectomy using epidural anesthesia, intrathoracic vagal blockade, and sedation. To evaluate the feasibility and safety of this novel technique, they were compared with a control group consisting of 30 consecutive patients with clinical stage I or II NSCLC who underwent thoracoscopic lobectomy using intubated general anesthesia from August 2008 through July 2009. Collapse of the operative lung and inhibition of coughing were satisfactory in the nonintubated patients, induced by spontaneous breathing, and vagal blockade. Three patients in the nonintubated group required conversion to intubated-single lung ventilation because of persistent hypoxemia, poor epidural anesthesia pain control, and bleeding. One patient in each group was converted to thoracotomy because of bleeding. The 2 groups had comparable anesthesia durations, surgical durations, blood loss, and numbers of dissected lymph nodes. Patients who underwent nonintubated surgery had lower rates of sore throat (6.7% vs 40.0%, P = 0.002) and earlier resumption of oral intake (mean, 4.7 hours vs 18.8 hours, P < 0.001). Patients undergoing nonintubated surgery also had a trend toward better noncomplication rates (90% vs 66.7%, P = 0.057) and shorter postoperative hospital stays (mean, 5.9 days vs 7.1 days, P = 0.078). Nonintubated thoracoscopic lobectomy is technically feasible and is as safe as lobectomy performed with intubation in highly selected patients. It can be a valid alternative of single-lung-ventilated thoracoscopic surgery in managing early-stage NSCLC.

31 March 2010 in Cancer Research
Verified
Journal Article
Closed access
PDF file
SCShih-Ting Cha
Shih-Ting Cha
PCPai-Sheng Chen
Pai-Sheng Chen
GJGunnar Johansson
Gunnar Johansson
CCChia-Yu Chu
Chia-Yu Chu
MWMing-Yang Wang
Ming-Yang Wang
MKMin-Liang Kuo
Min-Liang Kuo
Hypoxia-inducible factor-1α (HIF-1α) is widely considered to be one of the key regulators of tumor angiogenesis. The upstream regulation is complex and involves several growth factors, cytokines, and hypoxia. Herein, we have identified miR-519c as a hypoxia-independent regulator of HIF-1α, acting through direct binding to the HIF-1α 3′ untranslated region and leading to reduced tumor angiogenesis. Overexpression of miR-519c resulted in a significant decrease of HIF-1α protein levels and reduced the tube formation of human umbilical vein endothelial cells; similarly, antagomir inhibition of miR-519c increased the level of HIF-1α protein and enhanced angiogenic activity, suggesting an important role of miR-519c in HIF-1α–mediated angiogenesis. Consistent with the overexpression of miR-519c in cancer patients with better prognosis, mice injected with miR-519c–overexpressing cells exhibited dramatically reduced HIF-1α levels, followed by suppressed tumor angiogenesis, growth, and metastasis. In addition, we found that hepatocyte growth factor (HGF), a known HIF-1α inducer, reduced the miR-519c levels through an Akt-dependent pathway. This regulation was posttranscriptional and may be mediated by suppression of miR-519c maturation. Taken together, our findings provide the first evidence that miR-519c is a pivotal regulator of tumor angiogenesis and that microenvironmental HGF contributes to regulating miR-519c biogenesis in cancer cells. Cancer Res; 70(7); 2675–85

1 June 2004 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
WXWeiya Xia
Weiya Xia
JCJin-Shing Chen
Jin-Shing Chen
XZXian Zhou
Xian Zhou
PSPei-Rong Sun
Pei-Rong Sun
Dung-Fang LeeDung-Fang Lee
Dung-Fang Lee
MHMien-Chie Hung
Mien-Chie Hung
Purpose: The peripheral benzodiazepine receptor (PBR) expression has been shown dramatically increased in neoplastic tissues and tumor cell lines originated from ovary, liver, colon, breast, or brain relative to untransformed tissues. Its expression has been also associated with tumor progression and aggressiveness. To explore whether PBR expression level could be of prognostic value in invasive breast cancer, we studied a series of 117 patients who underwent surgery for primary breast carcinomas and were followed-up for 8 years.

1 February 2013 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
CWChun-Yu Wu
Chun-Yu Wu
JCJin-Shing Chen
Jin-Shing Chen
YLYi-Shiuan Lin
Yi-Shiuan Lin
TTTung-Ming Tsai
Tung-Ming Tsai
MHMing-Hui Hung
Ming-Hui Hung
YCYa-Jung Cheng
Ya-Jung Cheng

1 September 2011 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
PCPai-Sheng Chen
Pai-Sheng Chen
JSJen-Liang Su
Jen-Liang Su
SCShih-Ting Cha
Shih-Ting Cha
WTWoan-Yuh Tarn
Woan-Yuh Tarn
MWMing-Yang Wang
Ming-Yang Wang
MKMin-Liang Kuo
Min-Liang Kuo
MicroRNAs (miRNAs) influence many biological processes, including cancer. They do so by posttranscriptionally repressing target mRNAs to which they have sequence complementarity. Although it has been postulated that miRNAs can regulate other miRNAs, this has never been shown experimentally to our knowledge. Here, we demonstrate that miR-107 negatively regulates the tumor suppressor miRNA let-7 via a direct interaction. miR-107 was found to be highly expressed in malignant tissue from patients with advanced breast cancer, and its expression was inversely correlated with let-7 expression in tumors and in cancer cell lines. Ectopic expression of miR-107 in human cancer cell lines led to destabilization of mature let-7, increased expression of let-7 targets, and increased malignant phenotypes. In contrast, depletion of endogenous miR-107 dramatically increased the stability of mature let-7 and led to downregulation of let-7 targets. Accordingly, miR-107 expression increased the tumorigenic and metastatic potential of a human breast cancer cell line in mice via inhibition of let-7 and upregulation of let-7 targets. By mutating individual sites within miR-107 and let-7, we found that miR-107 directly interacts with let-7 and that the internal loop of the let-7/miR-107 duplex is critical for repression of let-7 expression. Altogether, we have identified an oncogenic role for miR-107 and provide evidence of a transregulational interaction among miRNAs in human cancer development.